Cancer Care Ontario | Action Cancer Ontario

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

142 Results

Guidelines and Advice

An Endorsement of the 2021 Cancer Care Alberta Clinical Practice Guideline on Uveal Melanoma

Status: Current
ID: C50-CIDAP-1

Mar 2024

Guidelines and Advice

Organizational Guidance for the Care of Patients with Central Nervous System Tumours in Ontario: Consensus Recommendations

Status: Current
ID: GL 9-11

Oct 2024

Guidelines and Advice

An Endorsement of the 2023 European Association of Urology (EAU) -American Society of Clinical Oncology (ASCO) Guidelines on Penile Cancer

Status: Current
ID: Guideline Endorsement C50-CIDAP-2

Nov 2024

Guidelines and Advice

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

Status: Current
ID: Guideline Endorsement C50-CIDAP-3

Mar 2025

Guidelines and Advice

Systemic Treatment Emergency Preparedness Guidance Document

Status: Current

Dec 1969

Guidelines and Advice

Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First-Line Chemotherapy

Status: Current
ID: 7-13
Version: 2

Updated

Sep 2025

Guidelines and Advice

An Endorsement of the ASCO-SNO Guideline on Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults

Status: Current
ID: GL END 9-10
Version: 2

Dec 1969

Guidelines and Advice

Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline

Status: Current
ID: 7-A-2022-1-17v3
Version: 3

Oct 2023

Guidelines and Advice

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: American Society of Clinical Oncology (ASCO) and Ontario Health (Cancer Care Ontario) Joint Guideline Update

Status: Current
ID: 7-A-2018-3

Dec 1969

Guidelines and Advice

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Status: Current
ID: 7-A-2018-2
Version: N/A

Jan 2020

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

An Endorsement of the 2021 Cancer Care Alberta Clinical Practice Guideline on Uveal Melanoma

Organizational Guidance for the Care of Patients with Central Nervous System Tumours in Ontario: Consensus Recommendations

An Endorsement of the 2023 European Association of Urology (EAU) -American Society of Clinical Oncology (ASCO) Guidelines on Penile Cancer

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

Systemic Treatment Emergency Preparedness Guidance Document

Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First-Line Chemotherapy

An Endorsement of the ASCO-SNO Guideline on Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults

Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: American Society of Clinical Oncology (ASCO) and Ontario Health (Cancer Care Ontario) Joint Guideline Update

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Pages